{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SARS-CoV-2+%28COVID-19%29+Severe+Pneumonia&page=5", "query": { "condition": "SARS-CoV-2 (COVID-19) Severe Pneumonia", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SARS-CoV-2+%28COVID-19%29+Severe+Pneumonia&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SARS-CoV-2+%28COVID-19%29+Severe+Pneumonia&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T09:51:46.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04369469", "title": "Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19 Severe Pneumonia", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Pneumonia, Viral" ], "interventions": [ { "name": "Ravulizumab", "type": "BIOLOGICAL" }, { "name": "BSC", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2020-05-10", "completion_date": "2021-04-08", "has_results": true, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04369469" }, { "nct_id": "NCT05624450", "title": "Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Viral Lung Infection and Acute Respiratory Failure" ], "interventions": [ { "name": "Tozorakimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3527, "start_date": "2022-12-13", "completion_date": "2027-11-04", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 75, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05624450" }, { "nct_id": "NCT04519437", "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Chronic Stable Illness" ], "interventions": [ { "name": "REGN10933+REGN10987", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 974, "start_date": "2020-07-26", "completion_date": "2021-11-22", "has_results": false, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 7, "location_summary": "Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04519437" }, { "nct_id": "NCT04425629", "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "casirivimab+imdevimab combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10078, "start_date": "2020-06-16", "completion_date": "2022-06-09", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 102, "location_summary": "Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04425629" }, { "nct_id": "NCT04518410", "title": "ACTIV-2: A Study for Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus", "Covid19" ], "interventions": [ { "name": "bamlanivimab 7000mg", "type": "BIOLOGICAL" }, { "name": "BRII-196+BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IV)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IM)", "type": "BIOLOGICAL" }, { "name": "SNG001", "type": "DRUG" }, { "name": "Camostat", "type": "DRUG" }, { "name": "BMS-986414 + BMS-986413", "type": "BIOLOGICAL" }, { "name": "SAB-185 (3,840 Units/kg)", "type": "BIOLOGICAL" }, { "name": "SAB-185 (10,240 Units/kg)", "type": "BIOLOGICAL" }, { "name": "CASIRIVIMAB + IMDEVIMAB", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 7000mg", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 700mg", "type": "DRUG" }, { "name": "Placebo for BRII-196+BRII-198", "type": "DRUG" }, { "name": "Placebo for SNG001", "type": "DRUG" }, { "name": "Placebo for Camostat", "type": "DRUG" }, { "name": "Placebo for SAB-185 (low dose)", "type": "DRUG" }, { "name": "Placebo for BMS-986414 + BMS-986413", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IV)", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IM)", "type": "DRUG" }, { "name": "Placebo for SAB-185 (high dose)", "type": "DRUG" }, { "name": "bamlanivimab 700mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4044, "start_date": "2020-08-19", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 207, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518410" }, { "nct_id": "NCT04720794", "title": "A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Covid19", "SARS (Severe Acute Respiratory Syndrome)", "Corona Virus Infection" ], "interventions": [ { "name": "Lucira COVID-19 All-In-One test kit", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Lucira Health Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 101, "start_date": "2020-09-25", "completion_date": "2020-10-20", "has_results": false, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 1, "location_summary": "Los Gatos, California", "locations": [ { "city": "Los Gatos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04720794" }, { "nct_id": "NCT04421508", "title": "A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "Coronavirus", "Coronavirus Infection" ], "interventions": [ { "name": "INOpulse", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Bellerophon Pulse Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2020-07-12", "completion_date": "2021-01-22", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 17, "location_summary": "Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421508" }, { "nct_id": "NCT04412668", "title": "Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2 (COVID-19) Severe Pneumonia" ], "interventions": [ { "name": "Efzofitimod 1 mg/kg", "type": "DRUG" }, { "name": "Efzofitimod 3 mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "aTyr Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2020-06-04", "completion_date": "2020-10-23", "has_results": true, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Annapolis", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04412668" }, { "nct_id": "NCT04335552", "title": "Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "Standard of care", "type": "OTHER" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 11, "start_date": "2020-04-17", "completion_date": "2020-06-26", "has_results": true, "last_update_posted_date": "2021-05-17", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 4, "location_summary": "Durham, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04335552" }, { "nct_id": "NCT05119855", "title": "Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papillomavirus Infections", "Coronavirus Disease (COVID-19)" ], "interventions": [ { "name": "9vHPV Vaccine", "type": "BIOLOGICAL" }, { "name": "mRNA-1273 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "9 Years to 11 Years" }, "enrollment_count": 165, "start_date": "2022-03-28", "completion_date": "2023-12-12", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-13T09:51:46.561Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05119855" } ] }